PDF herunterladen
Semin Liver Dis 2025; 45(02): 210-220
DOI: 10.1055/a-2435-2091
Review Article

Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease

Autoren

  • Aurora Barberá

    1   The Global NASH Council, Washington, District of Columbia
    2   Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain

  • Trenton M. White

    2   Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain

  • Anish K. Arora

    3   Department of Family and Community Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

  • Linda Henry

    1   The Global NASH Council, Washington, District of Columbia
    4   Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia

  • Jeffrey V. Lazarus

    1   The Global NASH Council, Washington, District of Columbia
    2   Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
    5   CUNY Graduate School of Public Health and Health Policy, New York City, New York

  • Zobair M. Younossi

    1   The Global NASH Council, Washington, District of Columbia
    4   Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia
    6   Center for Outcomes Research in Liver Disease (CORLD), Washington, District of Columbia

Funding The study was funded by the Global NASH Council and the Center for Outcomes Research i Liver Disease, Washington DC, USA AB, TMW and JVL acknowledge support to ISGlobal from the grant CEX2023-0001290-S funded by MCIN/AEI/ 10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Programme.
Weitere Informationen
   Lizenzen und Reprints


Graphical Abstract

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and can progress to serious complications, including metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Predisposing risk factors for MASH include obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome. Patients with MASH often experience significant impairments in their health-related quality of life and other patient-reported outcomes (PROs), particularly in physical functioning domains, fatigue, and vitality. Incorporating PROs offers valuable insights into patients' perspectives on their symptoms, treatment efficacy, and overall well-being, thereby guiding more holistic and patient-centered care strategies. This review aims to investigate the utilization of patient-reported outcome measures (PROMs) in the context of MASLD and MASH care, identify which PROMs are employed, and summarize the outcomes reported.

Keywords

MASH - quality of life - MASLD - HRQoL - person-centered care

Disclosures

Z.M.Y. has received research funding and/or served as consultant to Intercept, CymaBay, Boehringer Ingelheim, BMS, GSK, NovoNordisk, Ipsen, AstraZeneca, Siemens, Madrigal, Merck, and Abbott.


J.V.L. acknowledges grants to ISGlobal from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal, MSD, Novo Nordisk, Pfizer, and Roche Diagnostics; consulting fees from Echosens, NovoVax, GSK, Novo Nordisk, and Pfizer; and payment or honoraria for lectures from AbbVie, Echosens, Gilead Sciences, Janssen, Moderna, MSD, Novo Nordisk, and Pfizer, outside of the submitted work.


Authors' Contributions

A.B. developed the preliminary outline. A.B., T.M.W., and A.K.A. conducted the literature review and drafted the manuscript. J.V.L. supervised the initial draft and critically reviewed the content. L.H. and Z.M.Y. contributed to the conception of the article and provided critical revisions. Z.M.Y. provided the oversight. All authors approved the manuscript for submission.


Supplementary Material



Publikationsverlauf

Accepted Manuscript online:
07. Oktober 2024

Artikel online veröffentlicht:
14. November 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA